v3.26.1
EQUITY (Tables)
12 Months Ended
Dec. 31, 2025
Equity [Abstract]  
SCHEDULE OF STOCK WARRANTS OUTSTANDING TO PURCHASE COMMON STOCK

As of December 31, 2025, the Company had the following outstanding warrants to purchase common stock:

 

             Number of 
             Shares of 
         Exercise Price   common stock 
   Issuance  Expiration  Per Share   Underlying 
Warrant  Date  Date  ($)   Warrants 
               
March 2021 Warrant  March 29, 2021  March 31, 2026   10.35    2,469,156 
March 2023 Warrant  March 27, 2023  March 26, 2026   5.50    3,294,117 
               5,763,273 
SCHEDULE OF STOCK OPTION ACTIVITY

The following summarizes stock option activity:

 

   Amount of options   Weighted average exercise price   Weighted Average Remaining Contractual Term (years)   Aggregate Intrinsic Value (in thousands) 
       $       $ in
thousands
 
Outstanding - January 1, 2024   2,455,069    3.46    5.04    312 
Granted   795,500    4.77    -    - 
Forfeited   (23,335)   3.00    -    - 
Outstanding - December 31, 2024   3,227,234    3.78    4.66    13,605 
                     
Granted   331,000    5.37    -    - 
Forfeited   (137,286)   3.94    -    - 
Exercised   (80,434)   3.36    -    - 
Outstanding - December 31, 2025   3,340,514    3.95    4.06    650 
                     
Options Exercisable - December 31, 2025   2,413,154    3.68    3.44    589 
SCHEDULE OF RESTRICTED STOCK UNIT (“RSU”) ACTIVITY

The following table summarizes RSU activity:

  

   Amount of RSUs   Weighted Average Grant Date Fair Value per Share   Weighted Average Remaining Contractual Term (years) 
         $          
Outstanding – January 1, 2024   39,585    4.08    6.3 
Granted   -    -    - 
Forfeited   -    -    - 
Vested   (24,166)   4.42    - 
Unvested and Outstanding - December 31, 2024   15,419    3.56    5.5 
Granted   -    -    - 
Forfeited   -    -    - 
Vested   (11,252)   3.76    - 
Unvested and Outstanding - December 31, 2025   4,167    3.0    4.72 
SCHEDULE OF STOCK-BASED PAYMENT EXPENSE

The following table sets forth the total stock-based payment expenses resulting from options and RSU granted, included in the statements of operation and comprehensive income:

 

   2025   2024 
   Year ended on
December 31,
 
   2025   2024 
   USD in thousands 
Cost of revenues   (3)   35 
Research and development   908    665 
Sales and marketing expenses   358    265 
General and administrative   1,815    1,421 
Total expenses   3,078    2,386